Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model

Magnetic Resonance Imaging

Volumn 30, Issue 7, 2012, Pages 1002-1009

  Cárdenas Rodríguez, Julio ^a,b   Li, Yuguo ^c   Galons, Jean Philippe ^b,d   Cornnell, Heather ^e   Gillies, Robert J ^e   Pagel, Mark D ^a,b,c   Baker, Amanda F ^b,f  

^a University of Arizona   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

^c University of Arizona   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^f UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Diffusion weighted MRI; Dynamic contrast enhanced MRI; TH 302; Tumor hypoxia

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; HYPOXIA INDUCIBLE FACTOR 1ALPHA; TH 302; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL KILLING; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DRUG RESPONSE; DYNAMIC CONTRAST ENHANCED MAGNETIC RESONANCE IMAGING; FEMALE; HUMAN; HUMAN CELL; HYPOXIA; IMAGE ANALYSIS; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS, PHARMACOLOGICAL; CELL LINE, TUMOR; DIFFUSION MAGNETIC RESONANCE IMAGING; FEMALE; MICE; MICE, SCID; NITROIMIDAZOLES; PANCREATIC NEOPLASMS; PHOSPHORAMIDE MUSTARDS; PRODRUGS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 84863999020     PISSN: 0730725X     EISSN: 18735894     Source Type: Journal    
DOI: 10.1016/j.mri.2012.02.015     Document Type: Article

References (24)

1. Cassavaugh J., Lounsbury K.M. Hypoxia-mediated biological control. J Cell Biochem 2011, 112:735-744.
2. Duffy J.P., Eibl G., Reber H.A., Hines O.J. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer 2003, 2:12-21.
3. Denny W.A. Hypoxia-activated prodrugs in cancer therapy: progress to the clinic. Future Oncol 2010, 6:419-428.
4. Duan J.X., Jiao H., Kaizerman J., Stanton T., Evans J.W., Lan L., et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem 2008, 51:2412-2420.
5. Hu J., Handisides D.R., Van Valckenborgh E., De Raeve H., Menu E., Vande Broek I., et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood 2010, 116:1524-1527.
6. Li S., Zhang J., Li J., Chen D., Matteucci M., Curd J., et al. Inhibition of both thioredoxin reductase and glutathione reductase may contribute to the anticancer mechanism of TH-302. Biol Trace Elem Res 2010, 136:294-301.
7. Liu Q., Sun J.D., Wang J., et al. TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules. Cancer Chemother Pharmacol 2012 Mar 2, [Epub ahead of print] PMID: 22382881.
8. Weiss G.J., Infante J.R., Chiorean E.G., Borad M.J., Bendell J.C., Molina J.R., et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res 2011, 17:2997-3004.
9. Evans C.E., Mattock K., Humphries J., Saha P., Ahmad A., Waltham M., et al. Techniques of assessing hypoxia at the bench and bedside. Angiogenesis 2011, 14:119-124.
10. Evelhoch J.L., Gillies R.J., Karczmar G.S., Koutcher J.A., Maxwell R.J., Nalcioglu O., et al. Applications of magnetic resonance in model systems: cancer therapeutics. Neoplasia 2000, 2:52-65.
11. Yankeelov T.E., Gore J.C. Dynamic contrast enhanced magnetic resonance imaging in oncology: theory, data acquisition, analysis, and examples. Curr Med Imaging Rev 2009, 3:91-107.
12. Jordan B.F., Runquist M., Raghunand N., Gillies R.J., Tate W.R., Powis G., et al. The thioredoxin-1 inhibitor 1-methylpropyl 2-imidazolyl disulfide (PX-12) decreases vascular permeability in tumor xenografts monitored by dynamic contrast enhanced magnetic resonance imaging. Clin Cancer Res 2005, 11:529-536.
13. Davis T.W., O'Neal J.M., Pagel M.D., Zweifel B.S., Mehta P.P., Heuvelman D.M., et al. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2-derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res 2004, 64:279-285.
14. Padhani A.R., Liu G., Koh D.M., Chenevert T.L., Thoeny H.C., Takahara T., et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia 2009, 11:102-125.
15. Morse D.L., Galons J.P., Payne C.M., Jennings D.L., Day S., Xia G., et al. MRI-measured water mobility increases in response to chemotherapy via multiple cell-death mechanisms. NMR Biomed 2009, 20:602-614.
16. Huang C.I., Kohno N., Ogawa E., Adachi M., Taki T., Miyake M. Correlation of reduction in MRP-1/CD9 and KAI1/CD82 expression with recurrences in breast cancer patients. Am J Pathol 1998, 153:973-983.
17. Tofts P.S., Brix G., Buckley D.L., Evelhoch J.L., Henderson E., Knopp M.V., et al. Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging 1999, 10:223-232.
18. Trouard T.P., Theilmann R.J., Altbach M.I., Gmitro A.F. High-resolution diffusion imaging with DIFRAD-FSE (diffusion-weighted radial acquisition of data with fast spin-echo) MRI. Magn Reson Med 1999, 42:11-18.
19. von Marschall Z., Cramer T., Höcker M., Burde R., Plath T., Schirner M., et al. De novo expression of vascular endothelial growth factor in human pancreatic cancer: evidence for an autocrine mitogenic loop. Gastroenterology 2000, 119:1358-1372.
20. Ali M.M., Janic B., Babajani-Feremi A., Varma N.R.S., Iskander A.S.M., Anagli J., et al. Changes in vascular permeability and expression of different angiogenic factors following anti-angiogenic treatment in rat glioma. PLoS One 2010, 5(1):e8727.
21. Kim H., Morgan D.E., Buchsbaum D.J., Zeng H., Grizzle W.E., Warram J.M., et al. Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging. Cancer Res 2008, 68:8369-8376.
22. Jordan B.F., Runquist M., Raghunand N., Baker A., Williams R., Kirkpatrick L., et al. Dynamic contrast-enhanced and diffusion MRI show rapid and dramatic changes in tumor microenvironment in response to inhibition of HIF-1A using PX-478. Neoplasia 2005, 7(5):475-485.
23. Yankeelov T.E., Lepage M., Chakravarthy A., Broome E.E., Niermann K.J., Kelley M.C., et al. Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging 2007, 25:1-13.
24. Barrett T., Gill A.B., Kataoka M.Y., Priest A.N., Joubert I., McLean M.A., et al. DCE and DW MRI in monitoring response to androgen deprivation therapy in patients with prostate cancer: a feasibility study. Magn Reson Med 2011, [epub ahead of print].